Chemotherapy of malignant melanoma

Luce, James K.

doi:10.1002/1097-0142(197212)30:6<1604::aid-cncr2820300629>3.0.co;2-5

Cited by 128 publications

(39 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The staging of malignant melanoma used is the Westminster Hospital Classification (Butterworth et al, 1974 A trend was observed for both treatment groups in that lymph node and skin deposits were more responsive to treatment than visceral deposits. The numbers are, however, too small to make significant statements, but the results are consistent with those of other authors (Wagner, Ramirez and Weiss, 1971;Luce, 1972;Einhorn et al, 1974). Immunotherapy appears to increase the response rate at certain sites and it should be noted that the (C + I) group contained more patients (13/19) with visceral involvement than group C (7/17).…”

Section: Methodssupporting

confidence: 89%

“…The one-year survival for Stage III was only 1000. These disappointing results are similar to the experience of others (Bodenham, 1968;Johnson and Jacobs, 1971;Luce, 1972). The most widely studied drug in disseminated malignant melanoma is DTIC, which has induced an objective regression rate in around 20% of cases in a number of series (summarized in Comis and Carter, 1974).…”

supporting

confidence: 81%

See 1 more Smart Citation

Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma

Newlands¹,

Oon²,

Roberts³

et al. 1976

Br J Cancer

View full text Add to dashboard Cite

Summary.-Fifty-six patients with disseminated malignant melanoma were randomly allocated to two treatment groups. The first group C received combination chemotherapy consisting of DTIC and ICRF 159. The second group (C + I) received the same chemotherapy but were also immunized with 2 x 107 irradiated allogeneic melanoma cells mixed with 50 ,ug of percutaneous BCG. The survival rates in both treatment groups C and (C + I) were not significantly different, and only minor enhancement of the chemotherapy was found in the (C + 1) group. A similar pattern of tissue response was observed in both groups: lymph node, skin and, to some extent liver metastases, respond better than other sites.THE CURRENT treatments for disseminated malignant melanoma are unsatisfactory. Analysis of the patients followed up at the Westminster Hospital in the pretrial period showed that the 2-and 5-year survivals for Stage IIb were 51°/ and 200% respectively. The

show abstract

Section: Methodssupporting

confidence: 89%

supporting

confidence: 81%

Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma

Newlands¹,

Oon²,

Roberts³

et al. 1976

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Consequently we were led to perform a pilot study to determine whether active immunotherapy using irradiated tumour cells could be (Luce, 1972 Histological confirmation of the diagnosis was made in all cases but so far examination of the original primary tumours and appropriate grading and classification studies are incomplete.…”

mentioning

confidence: 99%

Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study

Currie¹,

McElwain²

1975

Br J Cancer

View full text Add to dashboard Cite

In patients with disseminated malignant melanoma an optimal method of immunization with irradiated tumour cells was developed by reference to an in vitro assay for circulating specific serum inhibitors of cell mediated cytotoxicity. This immunization protocol consisted of the intradermal inoculation of 2 times 10(7) irradiated allogeneic melanoma cells admixed with 50 mug of percutaneous BCG. This method of immunization induced a significant but transient fall in the specific inhibitory effects of the sera on tumour directed cytotoxic activity of the patients' lymphocytes. In a pilot group of 30 patients with disseminated malignant melanoma being treated with chemotherapy (DTIC and vincristine) the immunotherapy was given midway between courses of the cytotoxic drugs. There was a correlation between the effects on circulating inhibitor and clinical outcome. The number of objective regressions occurring in this small pilot group was surprisingly high (17/30) and these clinical effects, although obtained in a series without concurrent controls, are presented for discussion. We suggest that the approach illustrated by this study, employing in vitro assays of tumour directed immune responses, may provide a suitable rational basis for the use of active immunotherapy as an adjunct to chemotherapy in the treatment of malignant disease.

show abstract

“…This opened the possibility of studying the relationship between the growth rate of the xenografts and their chemosensitivity. We report here on the effect of DTIC, CCNU and procarbazine, 3 of the most effective drugs in the treatment of human melanomas (Luce, 1972;Comis, 1976 Courtenay & Mills (1978). For each drug the different tumours showed the same relative sensitivity in vitro as found here in vivo (Tveit et al, submitted).…”

mentioning

confidence: 59%

An inverse relationship between the growth rate of human melanoma xenografts and their response to some cytostatic drugs

Fodstad¹,

Aass

Pihl

1980

Br J Cancer

View full text Add to dashboard Cite

Chemotherapy of malignant melanoma

Cited by 128 publications

References 57 publications

Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma

Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma

Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study

An inverse relationship between the growth rate of human melanoma xenografts and their response to some cytostatic drugs

Contact Info

Product

Resources

About